<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>United Therapeutics Corporation — News on 6ix</title>
<link>https://6ix.com/company/united-therapeutics-corporation</link>
<description>Latest news and press releases for United Therapeutics Corporation on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/united-therapeutics-corporation" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835d07778dffbe2df11f4b2.webp</url>
<title>United Therapeutics Corporation</title>
<link>https://6ix.com/company/united-therapeutics-corporation</link>
</image>
<item>
<title>United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors</title>
<link>https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-announces-retirement-of-professor-raymond-dwek-cbe-frs-from-its-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-announces-retirement-of-professor-raymond-dwek-cbe-frs-from-its-board-of-directors</guid>
<pubDate>Wed, 29 Apr 2026 12:00:00 GMT</pubDate>
<description>SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announce</description>
</item>
<item>
<title>United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026</title>
<link>https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-to-report-first-quarter-2026-financial-results-before-market-open-on-wednesday-may-6-2026</link>
<guid isPermaLink="true">https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-to-report-first-quarter-2026-financial-results-before-market-open-on-wednesday-may-6-2026</guid>
<pubDate>Wed, 22 Apr 2026 11:00:00 GMT</pubDate>
<description>SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 22, 2026--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2026 financial results in a press release that will be issued on Wednesday, May 6, 2026 at approximately 6:30 a.m. Eastern Time.</description>
</item>
<item>
<title>United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026</title>
<link>https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-presents-new-data-spanning-pulmonary-hypertension-treatment-lung-donor-expansion-and-xenotransplantation-at-ishlt-2026</link>
<guid isPermaLink="true">https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-presents-new-data-spanning-pulmonary-hypertension-treatment-lung-donor-expansion-and-xenotransplantation-at-ishlt-2026</guid>
<pubDate>Mon, 20 Apr 2026 10:30:00 GMT</pubDate>
<description>SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 20, 2026--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that 11 new data presentations across its commercial and development portfolio will be presented at the International Society for Heart and Lung Transplantation (ISHLT) 46th Annual Meeting and Scientific Sessions taking place April 22-25, 2026, in Toronto, Canada.</description>
</item>
<item>
<title>United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure</title>
<link>https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelapr-for-treatment-of-acute-liver-failure</link>
<guid isPermaLink="true">https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelapr-for-treatment-of-acute-liver-failure</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today</description>
</item>
<item>
<title>United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2</title>
<link>https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-announces-teton-1-pivotal-study-of-tyvasor-meets-primary-endpoint-for-treatment-of-idiopathic-pulmonary-fibrosis-exceeding-impressive-treatment-effect-seen-in-teton-2</link>
<guid isPermaLink="true">https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-announces-teton-1-pivotal-study-of-tyvasor-meets-primary-endpoint-for-treatment-of-idiopathic-pulmonary-fibrosis-exceeding-impressive-treatment-effect-seen-in-teton-2</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>Nebulized Tyvaso® (treprostinil) Inhalation Solution demonstrated superiority over placebo for the change in absolute forced vital capacity by 130.1 mL and</description>
</item>
<item>
<title>United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine</title>
<link>https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-announces-full-results-of-teton-2-phase-3-clinical-trial-published-in-the-new-england-journal-of-medicine</link>
<guid isPermaLink="true">https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-announces-full-results-of-teton-2-phase-3-clinical-trial-published-in-the-new-england-journal-of-medicine</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>The pivotal study of Tyvaso® (treprostinil) Inhalation Solution demonstrated a statistically significant preservation of lung function across all subgroups,</description>
</item>
<item>
<title>United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program</title>
<link>https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-announces-dollar2-billion-stock-repurchase-authorization-and-enters-into-dollar15-billion-accelerated-share-repurchase-program</link>
<guid isPermaLink="true">https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-announces-dollar2-billion-stock-repurchase-authorization-and-enters-into-dollar15-billion-accelerated-share-repurchase-program</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>Agreements for aggregate $1.5 billion Accelerated Share Repurchase (ASR) already executed, with an additional $500 million authorized within the next year</description>
</item>
<item>
<title>United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference</title>
<link>https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-to-present-at-the-leerink-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-to-present-at-the-leerink-global-healthcare-conference</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine</description>
</item>
<item>
<title>United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy</title>
<link>https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-announces-ralinepag-achieved-55percent-reduction-in-risk-of-clinical-worsening-in-pivotal-pulmonary-arterial-hypertension-study-delivering-exceptional-highly-statistically-significant-efficacy</link>
<guid isPermaLink="true">https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-announces-ralinepag-achieved-55percent-reduction-in-risk-of-clinical-worsening-in-pivotal-pulmonary-arterial-hypertension-study-delivering-exceptional-highly-statistically-significant-efficacy</guid>
<pubDate>Mon, 02 Mar 2026 11:30:00 GMT</pubDate>
<description>SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., March 02, 2026--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its long-term pivotal phase 3 ADVANCE OUTCOMES study met its primary endpoint, with ralinepag reducing the risk of a clinical worsening event by 55% compared with placebo in patients with PAH (hazard ratio 0.45, 95% CI [0.33-0.62]; p<0.0001).</description>
</item>
<item>
<title>United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Wed, 25 Feb 2026 11:30:00 GMT</pubDate>
<description>SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., February 25, 2026--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2025. Full year 2025 revenues rose to a record $3.18 billion, reflecting 11% growth over 2024.</description>
</item>
<item>
<title>United Therapeutics Corporation to Present at the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-to-present-at-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-to-present-at-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz,</description>
</item>
<item>
<title>United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026</title>
<link>https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-report-fourth-120000987</link>
<guid isPermaLink="true">https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-report-fourth-120000987</guid>
<pubDate>Wed, 11 Feb 2026 12:00:00 GMT</pubDate>
<description>SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., February 11, 2026--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2025 financial results before the market opens on Wednesday, February 25, 2026. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time.</description>
</item>
<item>
<title>United Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP® in Patients with Acute Liver Failure</title>
<link>https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-announces-positive-results-phase-1-study-miroliverelapr-patients</link>
<guid isPermaLink="true">https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-announces-positive-results-phase-1-study-miroliverelapr-patients</guid>
<pubDate>Mon, 26 Jan 2026 05:00:00 GMT</pubDate>
<description>This study was the world’s first FDA-cleared clinical trial using a bioengineered liver. Based on these positive results, United Therapeutics will initiate a</description>
</item>
<item>
<title>United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors</title>
<link>https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-announces-appointment-kevin-j-tracey-its-board</link>
<guid isPermaLink="true">https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-announces-appointment-kevin-j-tracey-its-board</guid>
<pubDate>Thu, 22 Jan 2026 05:00:00 GMT</pubDate>
<description>SILVER SPRING, Md. & DURHAM, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the</description>
</item>
<item>
<title>United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-present-44th-annual-jp-morgan-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-present-44th-annual-jp-morgan-healthcare-conference</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>SILVER SPRING, Md. & DURHAM, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairperson</description>
</item>
<item>
<title>United Therapeutics Corporation to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-present-upcoming-investor-conferences-2025-11-04</link>
<guid isPermaLink="true">https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-present-upcoming-investor-conferences-2025-11-04</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced</description>
</item>
<item>
<title>United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease</title>
<link>https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-announces-first-transplant-expand-clinical-trial</link>
<guid isPermaLink="true">https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-announces-first-transplant-expand-clinical-trial</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>Ongoing EXPAND Study is the First Clinical Trial to Evaluate Xenotransplantation in End-Stage Renal Disease SILVER SPRING, Md. & RESEARCH TRIANGLE PARK,</description>
</item>
<item>
<title>United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-reports-record-third-quarter-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-reports-record-third-quarter-2025-financial-results</guid>
<pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
<description>SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today</description>
</item>
<item>
<title>United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025</title>
<link>https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-report-third-quarter-2025-financial-results-market</link>
<guid isPermaLink="true">https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-corporation-report-third-quarter-2025-financial-results-market</guid>
<pubDate>Wed, 15 Oct 2025 04:00:00 GMT</pubDate>
<description>SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its</description>
</item>
<item>
<title>United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting</title>
<link>https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-feature-clinical-data-chest-2025-annual-meeting-2025-10-13</link>
<guid isPermaLink="true">https://6ix.com/company/united-therapeutics-corporation/news/united-therapeutics-feature-clinical-data-chest-2025-annual-meeting-2025-10-13</guid>
<pubDate>Mon, 13 Oct 2025 04:00:00 GMT</pubDate>
<description>SILVER SPRING, Md., & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today</description>
</item>
</channel>
</rss>